New Partnership Between Onboard Dynamics and T.D. Williamson Aims to Reduce Pipeline Emissions Across Eastern Hemisphere
5.6.2025 08:00:00 EEST | Business Wire | Press release
Onboard Dynamics LLC (“Onboard Dynamics”), a leading developer of pipeline evacuation technology, has entered into a strategic partnership with T.D. Williamson (“TDW”), a global provider of pipeline services and equipment. This collaboration will enable TDW to represent, market, and sell Onboard Dynamics’ products and services directly to customers across the Eastern Hemisphere through its own network of channel partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604551886/en/
Onboard Dynamics’ GoVAC® Pipeline Evacuation System—an innovative, self-powered mobile unit designed to capture and recover natural gas during pipeline evacuations, eliminating the need for venting or flaring. Pictured here in action during a pipeline drawdown project in France.
The partnership spans a broad and strategically important region—including Europe, Central Asia, the Middle East, Africa, India, and the Asia-Pacific—where the demand for sustainable pipeline solutions is rapidly growing. Together, the companies aim to support regional efforts to reduce carbon emissions by minimizing methane releases during pipeline evacuation operations.
“This partnership with Onboard Dynamics brings cutting-edge pipeline evacuation technology to our customers outside of North America,” said Laurent Fabry, Sr Director Sales Operations Europe Caspian & Africa at T.D. Williamson. “It enhances our ability to support clients in reducing emissions during natural gas pipeline maintenance, aligning with our shared commitment to environmental stewardship and service excellence.”
Mitch Schmidtke, CEO of Onboard Dynamics, added: “The importance of this strategic partnership with TDW cannot be overstated. It validates the strength of our technology and significantly accelerates our global reach. Together, we are equipping the natural gas pipeline industry in the Eastern Hemisphere with the tools needed to meet both operational and environmental goals.”
By combining TDW’s renowned quality service and technical expertise with Onboard Dynamics’ emissions-reducing technology, the partnership delivers comprehensive pipeline integrity and emissions management solutions.
About Onboard Dynamics LLC
Founded in 2013, the goal of Onboard Dynamics is to support the natural gas ecosystem in reducing global greenhouse gas (GHG) emissions safely and reliably through innovative and practical commercial solutions. Our compression-based systems minimize methane and other GHG releases during pipeline operations and maintenance. Learn more at: www.onboarddynamics.com.
About T.D. Williamson
T.D. Williamson (TDW) draws upon more than 100 years of industry expertise and experience to help operators of pressurized pipeline systems keep the world's energy lifelines running safely and reliably. TDW delivers an unmatched, patented portfolio of technology, products and services for the life of a pipeline including pigging, hot tapping and isolation, integrity assessment and repair to support operators in protecting the environment and moving toward a more sustainable energy future. Find out more at www.tdwilliamson.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250604551886/en/
Contacts
Media Contact:
Jason Vosburgh
Director of Marketing
Onboard Dynamics
Jason.vosburgh@onboarddynamics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom